NCT01498172View on ClinicalTrials.gov

BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients

PHASE1CompletedINTERVENTIONAL

Enrollment

23

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

February 28, 2015

Conditions

Bladder Cancer

Interventions

BIOLOGICAL

MAGE-A3 ASCI

5 doses every 3 weeks

BIOLOGICAL

BCG

1 intravesical dose /week for 6 weeks

Trial Locations (1)

1011

Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

Ludwig Center for Cancer Research of Lausanne

OTHER

collaborator

GlaxoSmithKline

INDUSTRY

lead

Patrice Jichlinski

OTHER

NCT01498172 - BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients | Biotech Hunter | Biotech Hunter